PBYI vs. ACIU, AQST, ME, IMMP, VSTM, TSVT, ALDX, XBIT, FHTX, and PYXS
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include AC Immune (ACIU), Aquestive Therapeutics (AQST), 23andMe (ME), Immutep (IMMP), Verastem (VSTM), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), XBiotech (XBIT), Foghorn Therapeutics (FHTX), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune (NASDAQ:ACIU) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
AC Immune has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of 0.00%. AC Immune's return on equity of 35.49% beat Puma Biotechnology's return on equity.
Puma Biotechnology has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Puma Biotechnology had 15 more articles in the media than AC Immune. MarketBeat recorded 17 mentions for Puma Biotechnology and 2 mentions for AC Immune. Puma Biotechnology's average media sentiment score of 1.05 beat AC Immune's score of 0.43 indicating that AC Immune is being referred to more favorably in the media.
Puma Biotechnology received 283 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 66.58% of users gave Puma Biotechnology an outperform vote while only 62.16% of users gave AC Immune an outperform vote.
AC Immune presently has a consensus target price of $16.00, suggesting a potential upside of 577.97%. Puma Biotechnology has a consensus target price of $7.00, suggesting a potential upside of 45.83%. Given Puma Biotechnology's higher probable upside, equities analysts clearly believe AC Immune is more favorable than Puma Biotechnology.
51.4% of AC Immune shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 22.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Puma Biotechnology beats AC Immune on 13 of the 16 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
